TTNP Titan Pharmaceuticals, Inc.

2.40
+0.15  (7%)
Previous Close 2.25
Open 2.25
Price To book 4.50
Market Cap 50.89M
Shares 21,203,000
Volume 143,552
Short Ratio 16.46
Av. Daily Volume 96,930

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 PK trial to be initiated 3Q 2017.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Edited Transcript of TTNP earnings conference call or presentation 10-May-17 8:15pm GMT
  2. TTNP: First Quarter Results; Development Programs on Track.
  3. Titan Pharmaceuticals reports 1Q loss
  4. Titan Pharmaceuticals Reports First Quarter 2017 Financial Results
  5. ETFs with exposure to Titan Pharmaceuticals, Inc. : May 5, 2017
  6. Titan Pharmaceuticals Schedules Conference Call To Review First Quarter 2017 Financial Results
  7. ETFs with exposure to Titan Pharmaceuticals, Inc. : March 27, 2017
  8. TTNP: 2016 Results; Deep Dive on Development Programs
  9. Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
  10. Titan Pharmaceuticals Reports Full Year And Fourth Quarter 2016 Financial Results
  11. Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results
  12. Titan Pharmaceuticals To Present At 29th Annual ROTH Conference
  13. Titan Pharmaceuticals Receives FDA Communication On Ropinirole Implant Investigational New Drug Application
  14. Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
  15. Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services
  16. Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
  17. Titan Pharmaceuticals Appoints Two New Board Members
  18. Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828542
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17769837
  3. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17693515
  4. 8-K - Current report 17683175
  5. 8-K - Current report 17644251
  6. 8-K - Current report 17639503
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17592921
  8. 8-K - Current report 17515828
  9. 8-K - Current report 17503655
  10. 8-K - Current report 162002886